BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

Clinical data showed a 45% objective response rate and 88% disease control rate in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, including those with concurrent T790M mutations. The results address a difficult-to-treat population with no approved targeted therapies and could support meaningful value creation for the therapy developer.